There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake. Even so, almost all endpoints in the so-called "negative" meta-analyses leaned toward a trend for benefit with a near 10% reduction in cardiovascular outcomes and a borderline statistical significance. Many trials included in these meta-analyses tested an insufficient daily dose of omega-3 PUFA of less than 1000 mg. Probably, the consistent cardiovascular effects of omega-3 PUFA supplements could be expected only with daily doses above 2000 mg.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112138PMC
http://dx.doi.org/10.1186/s12933-018-0766-0DOI Listing

Publication Analysis

Top Keywords

omega-3 pufa
20
effects omega-3
12
dosage duration
12
omega-3 polyunsaturated
8
polyunsaturated fatty
8
fatty acids
8
supplementation patients
8
patients diabetes
8
diabetes cardiovascular
8
cardiovascular disease
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!